CN1036046C - Preparation for cantharidia liposoluble pharmaceutics - Google Patents
Preparation for cantharidia liposoluble pharmaceutics Download PDFInfo
- Publication number
- CN1036046C CN1036046C CN91110970A CN91110970A CN1036046C CN 1036046 C CN1036046 C CN 1036046C CN 91110970 A CN91110970 A CN 91110970A CN 91110970 A CN91110970 A CN 91110970A CN 1036046 C CN1036046 C CN 1036046C
- Authority
- CN
- China
- Prior art keywords
- cantharidin
- preparation
- fat
- soluble
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method for preparing a fat-soluble cantharidin intermediate preparation, and a new series of antiviral and antibiotic preparations from the prepared intermediate preparation as an active component. In the fat-soluble cantharidin intermediate preparation of the present invention, a special technological method that the solubility and the dissolving stability of cantharidin are increased by using cantharides oil at proper dissolving temperature is adopted. The clinical treatment of the new prepared medicine indicates that medicine containing fat-soluble cantharidin is specific medicine for treating virus infection, such as viral hepatitis, viral enteritis, trachitis, condyloma acuminatum, etc. In addition, by using the fat-soluble cantharidin intermediate preparation, a series of fat-soluble cantharidin preparations with external-application local medicine effect, which are used for treating virus infection, can be prepared.
Description
The invention belongs to the preparation method of medicine, specifically, cantharidin and Oleum Mylabris are made fat-soluble intermediate preparation, again intermediate preparation is prepared into various fat-soluble cantharidin anti-virus formulations by extracting cantharidin and Oleum Mylabris in the insecticide Mylabris body.
Cantharidin is by what extract in the insecticide Mylabris body the hypertoxicity material to be arranged.Cantharis medically has the record of antitumor action very early as medicine in China.External classic Mylabris plaster is to be aided with Cera Flava, Colophonium, Adeps Bovis seu Bubali, the made vesicatory of Lignum Pini Nodi wet goods by powder of cantharide, powder of cantharide accounts for 25% in this cream, do not have through Calculation of Solubility and experimental observation cantharidin major part in system cream process dissolved, so this classic dermerethistica manufactured goods that are powder of cantharide.In recent years, found particularly that cantharidin can be used as after the anticarcinogen, the pharmacology of cantharidin and the research of using on clinical medicine had been developed by leaps and bounds.The method that at present prepares cantharidin and adopted is to utilize organic solvent, for example extracting from powder of cantharide such as acetone, chloroform.Increase yield for impelling cantharidate to change into cantharidin, so usually before, all will handle powder of cantharide with concentrated hydrochloric acid with organic solvent extracting cantharidin.And contain the preparation of cantharidin, also be non-liposoluble preparation, for example, cantharidin sheet (Shanghai Q/WS-1-566-80) and cantharidin injection (Shanghai Q/WS-1-567-80).
In recent years find again medically that cantharidin is a kind of antiviral antibiotic, but cantharidin is also not obvious in the common non-fat-soluble cantharidin preparation reaction of the intravital this antibiosis drug effect of humans and animals, and fat-soluble cantharidin demonstrates good effect (Nature Journal was rolled up 458 pages of 6 phases in 1980 3).Particularly, utilize fat-soluble cantharidin prepared preparation can play specific effect to the treatment of viral infection such as viral hepatitis.But as the serial antiviral drugs that preparation and this class of modern Western medicine cantharidia liposoluble pharmaceutics contains cantharidia liposoluble pharmaceutics still find no report.
The present inventor once provided a kind of method for preparing the fat-soluble intermediate preparation of cantharidin (Chinese patent application number be 90106365.7) in early days and utilized the base stock of prepared this intermediate preparation as active ingredient, the variant adjuvant of compatibility is prepared into a series of antiviral antibiotic preparation.This class medicine, to viral infection such as viral hepatitis, specific therapeutical effect.
This fat-soluble cantharidin intermediate preparation reaches the method that is prepared agent by this intermediate preparation, shown in production procedure Fig. 1.Among Fig. 1: 1, destructor; 2, lixiviate jar I; 3, lixiviate jar II; 4, separator I; 5, separator II; 6, separator III; 7, treatment tank I; 8, treatment tank II; 9, preparation still; 10, pharmacy still.
Wherein, destructor 1 is made up of pulverizer and two ones in exsiccator, the dry and pulverizing with the raw material cantharis in destructor 1; Lixiviate jar I2, II3 are made by rustless steel, pottery or glass material, utilize organic solvent or acid to add organic solvent in this jar Mylabris is flooded; The material that separator I4, II5, III6 make is identical with the lixiviate jar, by separator can be with solution biphase or solid-liquid two be separated; Treatment tank I7 makes with extra care product; Among the treatment tank II8 raw oil material is made with extra care; In the preparation still 9, cantharidin is made fat-soluble cantharidin intermediate preparation, and be processed into the various preparations that contain fat-soluble cantharidin in pharmacy still 10, preparation still 9 and pharmacy still 10 are to control its temperature, the pharmaceutical equipment of rustless steel, pottery or glass.
The following step is mainly adopted in the preparation of fat-soluble cantharidin preparation:
1, at first use organic solvent, for example dipping powders of cantharide such as acetone, chloroform, dichloromethane, chloroform arrive organic facies with the composition extracting of Oleum Mylabris in the Mylabris and cantharidin;
2, after the powder of cantharide drying through the organic solvent extracting, reuse concentrated hydrochloric acid and acetone soln flood, and concentrated hydrochloric acid can change into cantharidin with cantharidate, and acetone can dissolve cantharidin into organic facies;
3, cantharidin and Oleum Mylabris in above-mentioned 1 the organic facies are isolated from this organic facies after, add petroleum ether, the Oleum Mylabris extracting is gone out, and cantharidin is separated with Oleum Mylabris, cantharidin that obtains and above-mentioned 2 isolating cantharidin merging;
4, add a certain amount of Oleum Mylabris and by being metered into cantharidin in refining oils and fats, under 80～210 ℃ of temperature, normal pressure stirs heating down, makes fat-soluble cantharidin intermediate preparation.
Above-mentioned refining oils and fats can adopt vegetable oil such as Oleum Glycines, Semen Maydis oil, Oleum Brassicae campestris, Oleum Helianthi, Oleum Sesami cocoa butter, also can adopt mineral oil such as fat such as lanoline, Ethyl linoleate, isopropyl myristate (or ester) and vaseline, white oil.Process in the fat-soluble cantharidin intermediate preparation of preparation can also add a certain amount of antioxidant simultaneously, for example lecithin, gallate ester, HBT, HBA, VE etc.Can prepare at last and contain cantharidin 0.04～0.12%, Oleum Mylabris 0.1～4%, the fat-soluble cantharidin intermediate preparation of antioxidant 0.02～2%.
Form greasy fatty acid and aliphatic alcohol, cantharidin also there is higher dissolubility, the objective of the invention is, the cantharidia liposoluble pharmaceutics made from fatty acid and aliphatic alcohol is provided, and with the base stock of prepared this intermediate preparation as active ingredient, other adjuvant of compatibility is prepared into the antiviral antibiotic preparation of series.
The technology that adopts the present inventor once to provide (application for a patent for invention number be CN90106365.7) is provided the preparation method of cantharidia liposoluble pharmaceutics of the present invention, it is characterized in that in the preparation process it being that a certain amount of cantharidin is added fatty acid, for example oleic acid, linoleic acid or other are the fatty acid of liquid and aliphatic alcohol for example to make fat-soluble cantharidin intermediate preparation in the aliphatic alcohol such as propylene glycol, glycerol (glycerol), Polyethylene Glycol down at room temperature (25 ℃).
Specifically, fat-soluble cantharidin intermediate preparation is pressed the step preparation:
(1) in destructor 1, Mylabris is being lower than and pulverizing under 55 ℃ of conditions and dry, obtaining exsiccant powder of cantharide;
(2) powder of cantharide enters lixiviate jar (I) 2 and uses organic solvent, and for example acetone floods, soaks more than 24 hours and the repeated multiple times diafiltration, isolates organic facies and enters separator (I) 4, and solid phase enters lixiviate jar (II) 3;
(3) solid phase Mylabris granulated slag enters lixiviate jar (II) 3, and with concentrated hydrochloric acid and acetone soln dipping Mylabris granulated slag, dip time should be more than 24 hours, and with the diafiltration of acetone repeated multiple times, isolate organic facies and enter separator (II) 5, the residue discharge;
(4) in the separator (I) 4, cantharidin and Oleum Mylabris in the organic facies of above-mentioned (2) are separated from organic solvent-acetone, acetone reclaims, and cantharidin and Oleum Mylabris enter separator (III) 6;
(5) in the separator (III) 6, add petroleum ether, Oleum Mylabris can be dissolved, in the separator (III) 6, cantharidin is separated with Oleum Mylabris, Oleum Mylabris is discharged, Oleum Mylabris dissolves refining repeatedly with petroleum ether, make refining Oleum Mylabris, and cantharidin enters in the treatment tank (I) 7;
(6) in the separator (II) 5 organic facies (there is not the concentrated hydrochloric acid of reaction and the salt that the reaction back generates) mutually and separates with inorganic, after the inorganic discharge mutually, organic solvent-acetone is separated with cantharidin again, cantharidin enters in the treatment tank (I) 7;
(7) in treatment tank (I) 7, cantharidin is cleaned with petroleum ether repeatedly, use acetone, ethanol equal solvent heating for dissolving repeatedly then, crystallisation by cooling can obtain the cantharidin crystallization.At last again to crystalline solid with the proper amount of acetone dissolving of heating repeatedly, more than the crystallisation by cooling secondary, can obtain pure crystal (containing cantharidin more than 99%).This crystal enters preparation still 9;
(8) in treatment tank (II) 8, fatty acid or aliphatic alcohol are made with extra care and to be sterilized, the oils and fats after refining enters preparation still 9;
(9) in preparation still 9, with cantharidin, after fatty acid or aliphatic alcohol add by a certain percentage, the Oleum Mylabris and the antioxidant that add metering again, (for example: lecithin, gallate ester, HBT, HBA, VE etc.), adding a small amount of Oleum Mylabris can increase and consolidate the dissolubility of cantharidin in fatty acid or aliphatic alcohol.In preparation still 9, under 80～210 ℃ of temperature, normal pressure stirs down, and heating then can make cantharidin be dissolved in fatty acid or the aliphatic alcohol, when temperature reaches 105 ℃ of left and right sides, cantharidin can be dissolved rapidly in fatty acid or aliphatic alcohol, improve its dissolution velocity of temperature again, can not significantly accelerate with the increase of temperature.In process of production, best heating for dissolving temperature is 102～110 ℃, can finish course of dissolution in 30 minutes.
The preparation process of process above-mentioned (1)～(9) can make and contain cantharidin 0.04～0.12%, Oleum Mylabris 0.1～4%, the fat-soluble cantharidin intermediate preparation of antioxidant 0.02～2%.
The intermediate preparation of said process preparation adds other adjuvant by a certain percentage and can prepare the various preparations that contain fat-soluble cantharidin.Preparation process is carried out in pharmacy still 10, and preparation condition and process are described further by embodiment.
The preparation of embodiment 1 cantharidin external application emulsifiable paste
Fat-soluble cantharidin external application emulsifiable paste is pressed following composition:
Cantharidin: 0.12～0.3g
Fatty acid: 250～300g
Oleum Mylabris: 1～12g
Antioxidant: 0.06～6g
Other ointment base (stearic acid, hard ester alcohol, spermol, Cera Flava, hydrogenated vegetable oil glyceryl monostearate etc.): 80～180g
Emulsifying agent (tween, span, newborn lark, peregal 0 or fabaceous lecithin): 30～100g
Antibacterial: an amount of
All the other distilled water total amount 1000g.In pharmacy still 10, with emulsifying agent, distilled water is made the emulsifying agent dispersion liquid, and other ointment base is fused in the cantharidin intermediate preparation of above-mentioned preparation, fully stirs merit down at 60～80 ℃ and grinds milk, is chilled to room temperature and gets the external application emulsifiable paste.
The preparation of embodiment 2 cantharidin oral latex emulsions
The cantharidin oral latex emulsion is pressed following composition:
Cantharidin: 0.04～0.10g
Oleum Mylabris: 0.1～4g
Antioxidant: 0.1～2g
Fatty acid: 80～100g
Emulsifying agent: 5～25g
Antiseptic: an amount of
Flavoring agent: an amount of
All the other distilled water: total amount 1000ml
In pharmacy still 10 with emulsifying agent, flavoring agent and a certain amount of distilled water stir or grind, become the emulsifying agent dispersion liquid, drop into the above-mentioned fat-soluble cantharidin intermediate preparation of making, under 60～80 ℃, continue to stir or grind to form colostrum, add antiseptic then and make even emulsion liquid three times in the homogenize of dispersing emulsification machine mesohigh.
The preparation of embodiment 3 fat-soluble cantharidin sheets
Fat-soluble cantharidin sheet is pressed following composition:
Cantharidin: 0.04～0.1g
Fatty acid 80～100g
Oleum Mylabris 0.1～4g
Antioxidant 0.2～2g
Other is a right amount of auxiliary materials
Total amount: 2000
In pharmacy still 10, add a certain amount of adjuvant and stir and make the adjuvant tablet earlier, then with fat-soluble cantharidin intermediate preparation under 40～60 ℃ of temperature, evenly infiltrate in the tablet, coating, promptly.
Embodiment 4 cantharidin injectable emulsions (vein)
The cantharidin injectable emulsion is pressed following composition:
Cantharidin: 0.03～0.05g
Oleum Mylabris: 0.1～2g
Fatty acid: 100-150g
Emulsifying agent (lecithin, general good Buddhist nun's gram or fabaceous lecithin): 7～15g
Glycerol: 0～20g
All the other are water for injection total amount 1000ml
In pharmacy still 10 with a certain amount of water for injection, emulsifying agent, glycerol are made the fabaceous lecithin dispersion liquid under nitrogen current, the fat-soluble cantharidin intermediate preparation input of above-mentioned preparation is made highly evenly Emulsion, get injectable emulsion through sterilization treatment again, the injectable emulsion preparation process is operated in blanket of nitrogen.
Except that embodiment 1～4, also can be made into fat-soluble cantharidin capsule, soft capsule, the cantharidia liposoluble pharmaceutics of general drug effects such as soft gelatin capsule or fat-soluble cantharidin electuary cantharidin smears.
In addition, have the fat-soluble cantharidin of antiviral antibiosis, also can make the medicine of local drug effect, people's external viral infection wound, burn and other inflammation all had outstanding anti-inflammatory analgetic drug effect.For example can be made into:
1, cantharidin medicine oil
It consists of:
Cantharidin: 0.0005～0.03g
Oleum Mylabris: 1～20g
Fatty acid: 900～990g
Antioxidant: 1～20g total amount 1000g
Sterilized fatty acid and above-mentioned fat-soluble cantharidin intermediate preparation are reached evenly in 102～110 ℃ of stirrings in the pharmacy still, promptly get medicine oil.
2, fat-soluble cantharidin aerosol
It consists of:
Cantharidin: 0.0001～0.02g
Aliphatic alcohol: 450～1000g
Oleum Mylabris: 1～20g
Antioxidant: 1～20g
Propellant is an amount of
Make 3000ml be about to sterilize the fat-soluble cantharidin intermediate preparation of compositions such as aliphatic alcohol and above-mentioned preparation in the pharmacy still at 102～110 ℃ of abundant stirring and evenly mixings, add an amount of propellant and make aerosol.
3, fat-soluble cantharidin vaginal suppository
It consists of:
Cantharidin 0.0001～0.03g
Antioxidant 0.5～2g
Aliphatic alcohol 300～800g
Oleum Mylabris 1～20g
Other substrate is an amount of
Make 1000g and be about to a certain amount of sterilization aliphatic alcohol, anhydrous lanolin, Cera Flava etc., the fat-soluble cantharidin intermediate preparation of adjuvant and above-mentioned preparation is in pharmacy still 0, and after 102～110 ℃ of stirrings were full and uniform, the cooling molding got suppository.
4, cantharidin eye ointment
It consists of:
Cantharidin: 0.0005～0.03g
Aliphatic alcohol: 700～900g
Oleum Mylabris: 1～20g
Antioxidant: 0.2～20g
Other substrate is an amount of
Make 1000g and the fat-soluble cantharidin intermediate preparation of above-mentioned preparation is added sterilization aliphatic alcohol and other substrate constantly stir down at 102～110 ℃ and make full and uniformly, cooling promptly.
5, cantharidin ointment
Cantharidin ointment is pressed following composition:
Cantharidin: 0.0005～0.05g
Antioxidant: 0.2～20g
Fatty acid: 700～900g
Oleum Mylabris: 1～20g
Other ointment base (stearic acid, Cera Flava, stearyl alcohol etc.) is an amount of
Make 1000g
Add sterilization fatty acid, other ointment base in pharmacy still 10, the fat-soluble cantharidin intermediate preparation of above-mentioned preparation is dropped in the pharmacy still 10, maintain the temperature at 102～110 ℃, stir minute, make fully evenly, the elimination residue obtains ointment.
6, fat-soluble cantharidin rubber plaster
It consists of:
Cantharidin: 0.005～0.1g
Fatty acid or aliphatic alcohol: 80～100g
Oleum Mylabris: 0.1～4g
Antioxidant: 0.04～4g
Other substrate (as anhydrous lanolin, liquid Paraffin) 120～180g
Raw rubber: 350～460g
Collophony: 400～500g
Zinc oxide fine powder: 500～570g
Other adjuvant: an amount of
Gasoline: an amount of
Make: 1500g
Cream thickness is: 1.2～1.5g/100cm
2At first rubber is dissolved in the gasoline, makes rubber cement, add fat-soluble cantharidin intermediate preparation and other raw material of above-mentioned preparation then, mixing is applied on the calico with the coating machine, makes the rubber plaster behind the gasoline volatilization.
Utilization also can be made into fat-soluble cantharidin supp anal similar in appearance to above-mentioned method, cantharidin eye oil, the cantharidia liposoluble pharmaceutics of local drug effects such as fat-soluble cantharidin liniment.
The curative effect of embodiment 5 fat-soluble cantharidin treatment viral hepatitis
Utilize the fat-soluble cantharidin preparation of the embodiment of the invention 1～4 preparation that Patients with Viral Hepatitis is treated, contrast Radix Isatidis injection intramuscular injection.Treatment case 50 examples, contrast case 25 examples, medication is as follows:
Treatment group (the fat-soluble cantharidin preparation of embodiment 1～4 preparation, oral or external)
Dosage: cantharidin 0.01～0.025mg/kg/ day.
Matched group (Radix Isatidis injection intramuscular injection)
Dosage: a twice-daily, the statistical result of 1～2 its treatment such as table 1, table 2, table 3, term is as giving a definition in the table:
1, symptom significantly takes a turn for the better: refer to anorexia, weak, detest in three kinds of symptoms of oil two or more remarkable improvement;
2, transference cure: appetite reaches normally, does not mind oil, and antisecosis is normal;
3, acute hepatitis is failed to respond to any medical treatment: medication loseed subjective symptoms in 5 days and is clearly better to invalid.
4, chronic hepatitis treatment is invalid: medication loseed subjective symptoms in 10 days and is clearly better to invalid.
Result by above embodiment shows that the preparation that utilizes the present invention to prepare is a kind of effective medicine of treatment viral hepatitis.Also prove by other clinical trial, use the invention provides the technology preparation medicament to viral enteritis, tracheitis, sharp dehumidification wart etc. because the disease that virus is caused all has better therapeutic effect.
Cantharidin is mainly chemically examined the diagnostic data table before treating acute and chronic medicine for curing hepatitis
Table 1
| The project grouping | Case load | GPT | Icterus index | ||||
| Raise | Normally | 40～90u | 15～39u | 7～14u | 6u↓ | ||
| Contrast | 15 | 15 | 3 | 4 | 8 | ||
| Acute hepatitis | 35 | 35 | 11 | 7 | 1 | 16 | |
| Contrast | 10 | 7 | 3 | 2 | 3 | 5 | |
| Chronic hepatitis | 15 | 11 | 4 | 1 | 2 | 2 | 10 |
Cantharidin is treated acute and chronic hepatitis effective percentage statistical table table 2
| The project grouping | Case load | Effective case load | Effective percentage % | The P value |
| Matched group | 25 | 14 | 56 | |
| The treatment group | 50 | 48 | 96 | ＜0.01 |
Cantharidin is treated the effective patient's curative effect of acute and chronic hepatitis progress statistical table table 3
| The project grouping | Symptom significantly take a turn for the better (average day) | Transference cure (average day) | Liver obviously bounce back (average day) | After the treatment sequela that chemical examination has reached normal (average day) | The P value | |
| Contrast | 4.6 | 25.9 | 30.6 | 38.8 | 52.5 | |
| Acute non-hepatitis B | 1.6 | 4.9 | 6.6 | 18.3 | 24.1 | ＜0.01 |
| Contrast | 8.5 | 29.0 | ||||
| Chronic non-hepatitis B | 3.7 | 19.3 | 23.5 | 29.7 | ＜0.01 | |
| Contrast | 4.3 | 25.6 | ||||
| Acute hepatitis B | 2.5 | 5.9 | 7.8 | 28.5 | 38.2 | ＜0.01 |
| Contrast | 9.5 | 31.0 | ||||
| Chronic hepatitis B | 6.3 | 16.6 | 19.2 | 32.5 | ＜0.01 | |
Claims (9)
1. the preparation method of a fat-soluble cantharidin intermediate preparation, comprise with acid treatment insecticide powder of cantharide and utilize organic solvent from powder of cantharide, to extract cantharidin, it is characterized in that in the preparation process cantharidin added and be prepared into fat-soluble cantharidin preparation in fatty acid or the aliphatic alcohol, used fatty acid is an oleic acid, linoleic acid or other are the fatty acid of liquid at normal temperatures, aliphatic alcohol is propylene glycol, glycerol or Polyethylene Glycol.
2. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation and ointment base are evenly made emulsifiable paste in 60～80 ℃ of abundant down stirrings or grinding, this emulsifiable paste is composed as follows:
Cantharidin: 0.12～0.3g
Fatty acid: 250～300g
Oleum Mylabris: 1～12g
Antioxidant: 0.06～6g
Ointment base: 80～180g
Emulsifying agent: 30～100g
Antibacterial: an amount of
All the other distilled water: total amount 1000g.
3. according to the preparation method of claim 1, it is characterized in that with fat-soluble cantharidin intermediate preparation and fatty acid that ointment base stirs under 102～110 ℃ of temperature, makes ointment, this ointment is composed as follows:
Cantharidin: 0.0005～0.05g
Oleum Mylabris: 1～20g
Antioxidant: 0.2～20g
Fatty acid: 700～900g
Ointment base: an amount of
Make: 1000g.
4. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation stirred under 60～80 ℃ of temperature or grind with ointment base evenly becoming colostrum, dispersing emulsification machine mesohigh homogenize three times, make Emulsion then, this Emulsion is composed as follows:
Cantharidin: 0.04～0.1g
Oleum Mylabris: 0.1～4g
Antioxidant: 0.1～2g
Fatty acid: 80～100g
Emulsifying agent: 5～25g
Antiseptic: an amount of
Flavoring agent: an amount of
All the other distilled water: total amount 1000ml.
5. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation is evenly infiltrated under 40～60 ℃ of temperature in the adjuvant tablet, coating gets tablet, and this tablet is composed as follows:
Cantharidin: 0.04～0.1g
Fatty acid: 80～100g
Oleum Mylabris: 0.1～4g
Antioxidant: 0.2～2g
Adjuvant: an amount of
Make: 2000.
6. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation, injection and emulsifying agent are made injectable emulsion highly uniformly in nitrogen current this injectable emulsion composed as follows:
Cantharidin: 0.03～0.05g
Fatty acid: 100～150g
Oleum Mylabris: 0.1～2g
Emulsifying agent: 7～15g
Glycerol: 0～20g
All the other are water for injection total amount 1000ml.
7. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation and aliphatic alcohol, anhydrous lanolin or Cera Flava are stirred under 102～110 ℃, be cooled to 40～50 ℃ of molding and get suppository, this suppository composed as follows:
Cantharidin: 0.0005～0.03g
Antioxidant: 0.5～2g
Fatty acid: 300～800g
Oleum Mylabris: 1～20g
Substrate: an amount of
Make: total amount is 1000g.
8. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation and substrate stirred under 102～110 ℃ and make eye ointment, this eye ointment composed as follows:
Cantharidin: 0.0005～0.02g
Fatty acid: 700～900g
Oleum Mylabris: 1～20g
Antioxidant: 0.2～20g
Substrate: an amount of
Making total amount is: 1000g.
9. according to the preparation method of claim 1, it is characterized in that fat-soluble cantharidin intermediate preparation, antioxidant and propellant are made aerosol at 102～110 ℃ of abundant stirring and evenly mixings this aerosol composed as follows:
Cantharidin: 0.0001～0.02g
Fatty acid: 450～1000g
Oleum Mylabris: 1～20g
Antioxidant: 1～20g
Propellant: an amount of
Make: 3000ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91110970A CN1036046C (en) | 1991-12-10 | 1991-12-10 | Preparation for cantharidia liposoluble pharmaceutics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91110970A CN1036046C (en) | 1991-12-10 | 1991-12-10 | Preparation for cantharidia liposoluble pharmaceutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1073096A CN1073096A (en) | 1993-06-16 |
| CN1036046C true CN1036046C (en) | 1997-10-08 |
Family
ID=4910381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91110970A Expired - Fee Related CN1036046C (en) | 1991-12-10 | 1991-12-10 | Preparation for cantharidia liposoluble pharmaceutics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1036046C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190190C (en) * | 2001-11-23 | 2005-02-23 | 王卫 | Antiviral and antibacterial cantharidinic anhydride medicine composition and its prepn process |
| CN1449752A (en) * | 2003-05-09 | 2003-10-22 | 王卫 | Cantharidin total anhydride pharmaceutics for treating and preventing SARS and preparation thereof |
| CN108114003A (en) * | 2018-02-27 | 2018-06-05 | 张显英 | A kind of fermenting extraction process of Chinese blister beetle stoste |
| CN111568897A (en) * | 2020-05-25 | 2020-08-25 | 甘肃芫美药业有限公司 | An antiviral and antibacterial cantharidin preparation, its preparation method, and its application in preventing and treating new coronavirus infection |
-
1991
- 1991-12-10 CN CN91110970A patent/CN1036046C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 中草药，89年29卷3期 1989.1.1 朱传光，邓正已，"玫王蝥的研究概况";中草药89年 朱传光，邓正已"斑蝥的研究概况" * |
| 中草药，89年29卷3期 1989.1.1 朱传光，邓正已，"玫王蝥的研究概况" * |
| 中草药89年 朱传光，邓正已"斑蝥的研究概况" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1073096A (en) | 1993-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1824035A (en) | Swim bladder kidney nourishing preparation and its preparation method | |
| CN101066340A (en) | Compound externally applied tetrodotoxin ointment and its prepn | |
| CN1036046C (en) | Preparation for cantharidia liposoluble pharmaceutics | |
| CN1029771C (en) | Cantharidin fat-soluble medicament preparation | |
| CN1823910A (en) | Joint pain preparation and its new preparation method | |
| CN1301098C (en) | Hairy holly root drip pill and its preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1850264A (en) | Safflower preparation for treating wound and new preparing method | |
| CN1686123A (en) | Pyrolidone hydrochloride drip pill and its preparation method | |
| CN1748757A (en) | Dragon's blood external use preparation and its preparing method | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN104622875B (en) | Breast injection medicament for resisting cow mastitis and preparation method thereof | |
| CN1824109A (en) | Liaoyuanqili medicinal preparation and its new preparation method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1720946A (en) | Bone strengthening dripping pills with Premena fulva craib as raw material and method for preparing the same | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN1190190C (en) | Antiviral and antibacterial cantharidinic anhydride medicine composition and its prepn process | |
| CN1283246C (en) | Complex rheum officinale-radix scutellariae extract injecta for treating acute pancreatitis and preparing method thereof | |
| CN1042298C (en) | Pharmaceutical preparations and process for preparing same | |
| CN1686432A (en) | Earthworm drip pill and its preparation method | |
| CN1748764A (en) | Menstruation regulating and pregnancy promoting preparation and new preparing method | |
| CN1449752A (en) | Cantharidin total anhydride pharmaceutics for treating and preventing SARS and preparation thereof | |
| CN1768762A (en) | Novel drug administering route of pantocrine injection, its preparation process and novel indications | |
| CN1284528C (en) | Orally administered dripping pills prepared by hive body | |
| CN1634145A (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |